Third Time Lucky? Sun’s Ampyra Generic Appears On Course To Indian Debut
Executive Summary
Amid all the heat around the patents for Acorda Therapeutics’ multiple sclerosis therapy Ampyra (dalfampridine) in the US, Sun Pharma appears to have received a key approval for its generic version of the product in India setting the stage for a potential launch in the country.
You may also be interested in...
Acorda Investor Scopia Seeks Big Return From Sale Of The Company
Citing recent deals, hedge fund Scopia encouraged Acorda's board on Aug. 7 to pursue a sale, but the company believes its new strategy focused on Parkinson's disease is best for shareholders.
India To Streamline Tiered Trial Approval Process – Will It Lift Sponsor Outlook?
India plans pivotal tweaks to its three-layered review process for clinical trial-related clearances – a move that is expected to pare approval timelines significantly and improve predictability for sponsors who have been generally cautious, over the recent past, about placing studies in the country.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.